BiotechTube

CS-3150

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Severe Hypertension

Conditions

Severe Hypertension

Trial Timeline

Jun 1, 2016 → Feb 1, 2017

NCT ID
NCT02808026

About CS-3150

CS-3150 is a phase 3 stage product being developed by Daiichi Sankyo for Severe Hypertension. The current trial status is completed. This product is registered under clinical trial identifier NCT02808026. Target conditions include Severe Hypertension.

What happened to similar drugs?

20 of 20 similar drugs in Severe Hypertension were approved

Approved (20) Terminated (6) Active (0)
✅Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
✅tacrolimusAstellas PharmaApproved
✅AlefaceptAstellas PharmaApproved
✅CefiderocolShionogiApproved
✅Donepezil HClEisaiApproved
✅Donepezil Hydrochloride (Aricept)EisaiApproved
✅KHK4827-Active + KHK4827-PlaceboKyowa KirinApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (6)

NCT IDPhaseStatus
NCT02885662Pre-clinicalCompleted
NCT02807974Phase 3Completed
NCT02808026Phase 3Completed
NCT02807987Phase 3Completed
NCT02722265Phase 3Completed
NCT02448628Phase 2Completed

Competing Products

20 competing products in Severe Hypertension

See all competitors
ProductCompanyStageHype Score
Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
44
Drotrecogin alfa (activated)Eli LillyPhase 2
35
CT-P13 SC Auto-Injector + Placebo Auto-InjectorCelltrionPhase 3
44
CT-P17 + EU-approved HumiraCelltrionPhase 3
40
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
47
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
44
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
47
tacrolimusAstellas PharmaApproved
43
enzalutamideAstellas PharmaPhase 1
29
Isavuconazonium Injection [Cresemba] + PlaceboAstellas PharmaPhase 3
32
AlefaceptAstellas PharmaApproved
43
Placebo + SCD-044_Low Dose (Dose 1) + SCD-044_Intermediate Dose (Dose 2) + SCD-044_High Dose (Dose 3)Sun PharmaceuticalPhase 2
35
Tildrakizumab 100 mg + PlaceboSun PharmaceuticalPhase 3
44
Tildrakizumab + Placebo + Tildrakizumab + Tildrakizumab + Tildrakizumab + Etanercept + PlaceboSun PharmaceuticalPhase 2/3
42
CefiderocolShionogiApproved
50
eritoran tetrasodium + PlaceboEisaiPhase 3
40
Donepezil HClEisaiApproved
43
Donepezil Hydrochloride (Aricept)EisaiApproved
35
KHK4827 + PlaceboKyowa KirinPhase 3
40
KHK4827 + PlaceboKyowa KirinPhase 3
40